ESTRO-ACROP-based IORT guidelines: contents + dates + authors
EXPECTED DATES
CANCER SITES/TYPES RESPONSIBLE AUTHORS
15.09.2017 proposal FC, PP 15.10.2017 all authors circulation 15.11.2017 pre-definitive all topics 15.12.2017 definitive manuscript
BREAST CANCER APBI Boost
FS CL ES
15.09.2017 proposal FC, PP 15.10.2017 all authors circulation 15.11.2017 pre-definitive all topics 15.12.2017 definitive manuscript
RECTAL CANCER
cT4 cN+ (?) Oligorecurrent
HR CS
15.09.2017 proposal FC, PP 15.10.2017 all authors circulation 15.11.2017 pre-definitive all topics 15.12.2017 definitive manuscript
PANCREATIC CANCER Resected Border-line Urresected
FC MK
15.09.2017 proposal FC, PP 15.10.2017 all authors circulation 15.11.2017 pre-definitive all topics 15.12.2017 definitive manuscript
SOFT TISSUE SARCOMAS Extremity Retroperitoneal Trunk/Central (?)
FR CF
(?) take a decision on inclusion or not of these sub-categories. FR: Falk Roeder; CF: Carlos Ferrer; MJ: Marta Jayes; PP: Philip Poortmans; FC: Felipe Calvo; FS: Felix Sedlmayer; ES: Elena Sperk; CL: Cristina Leonardi; CS: Claudio Sole; MK: Marco Krengli; HR: Harm Rutten
ESTRO-IORT Working Group/Task Force Timeline (after 2017 ESTRO meeting to December 2017)
FR: Falk Roeder; CF: Carlos Ferrer; MJ: Marta Jayes; PP: Philip Poortmans; FC: Felipe Calvo; FS: Felix Sedlmayer; ES: Elena Sperk; CL: Cristina Leonardi; CS: Claudio Sole; MK: Marco Krengli; HR: Harm Rutten
INVOLVED MEMBERS
ACTION STATUS
MJ ESTRO office provide ACROP latest guidelines and minutes from 07.05.2017 meeting Received FC May 2017
FC ACROP Guidelines + recommendations (FC) circulation among responsible authors Done 01.06.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF
Elaboration proposal guidelines (ACROP based) by site/type and sent to FC + PP
Expected 15.09.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Review (FC + PP) and re-circulation all authors/all guidelines for comments Expected 15.10.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Working groups by cancer site/type submit a pre-definitive draft of guideline Agree already 15.11.207
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Definitive manuscripts available from all groups Agree already 15.12.2017
PP FC MJ
Submission to ACROP Agree already 31.12.2017
EBRT: external beam radiotherapy; CT: chemotherapy; Gy: Gray; Kv: Kilovoltaje
Table 1. Chronologic data analysis from a 25 years literature review period on IORT for
pancreatic cancer: unresectable disease (33 articles, 1.866 patients) or post- resected status (27 articles,
1.234 patients)
DISEASE STATUS
1981-1989
1990-1999
200-2009 2010-2016
UNRESECTABLE
# Studies
# Patients
References
11
446
24-34
11
374
35-45
8
670
46-53
3
376
22, 54-55
IORT
Dose range (Gy)
Mean dose (Gy)
Electron beam
10-40
20
100%
10-40
20
100%
10-30
20
100%
10-30
20
100%
EBRT delivered
> 50% pts
27 %
54%
87%
75%
Adjuvant CT
> 50% pts
36%
36%
50%
100%
Median Survival
Range (months)
Mean (months)
8-16
10
3-18
10
7-13
11
9-16
13
RESECTED
# Studies
# Patients
References
4
37
31,34,37,56
11
253
18,35,38,42,58,63
8
606
48,52,64,69
4
338
17,23,54,70
IORT
Dose range (Gy)
Mean dose (Gy)
Electron beam
250 Kv
10-40
25
100%
--
10-30
15
100%
--
10-25
15
100%
--
6-30
15
75%
25%
EBRT delivered
> 50% pts
75%
40%
75%
75%
Adjuvant CT
> 50% pts
25%
63%
75%
100%
Median Survival
Range (months)
Mean (months)
5-18
9,5
10-19
15
9-28
15
19-24
21
25 years
>3,000 patients
>60 publications
MGH: Massachusetts General Hospital
(*) Entire group
Table 3. Institutional contemporary experiences including IOERT component in unresectable/borderlilne
disease treated with neoadjuvant chemoradiation with or without induction FORFIRINOX.
PARAMETER
MAYO CLINIC 2013 (21)
MGH 2016 (20)
Period of analysis
2002 - 2010 2010 - 2015
Initial local status:
Unresectable
Borderline
Median T size
37 (77%)
11 (23%)
--
60 (88%)
8 (12%)
3,6 cm
Neoadjuvant therapy
Chemo-radiation
Induction FORFIRINOX
31
--
68
68
Resected
# patients
R0
R1
R2
17 (35%)
11 (64%)
5 (29%)
1 (5%)
41 (68%)
19 (46%)
16 (39%)
6 (14%)
IOERT
# patients
Dose range
28 (58%)
12.5 – 20Gy
16 (26%)
10 – 17Gy
Outcomes for resection + IOERT
Local control
Median OS
3 years OS
84% (*)
+ 20 months
+ 30% (*)
73.8%
35.1 months
+ 40%
Post 2000- Post-neadjuvant
125 patients >3 years OS… +30%
Target volumen description
Tumor residue
Normal tissues exposed
Normal tissues protected/movilized
Special conditions:
Vascular manipulation Others
IORT factors
Applicator size /diameter Beveled end (degrees)
Electron energy Isodose prescription
Total dose
Number of fields Report every parameter for every field Overlaping Field –within-a-field
Protections
Fluid stability
Time of beam on
Gantry angulation
In vivo dosimetry (system/site)
Integrated pre-IORT treatment factors
Surgery: type of resection /exposure Neoadyuvant
Chemoradiation (CRT) Induction chemotherapy + CRT
Table 3. Reporting parameters for IORT electrons beam procedures in pancreatic cancer.
ESTRO-IORT Working Group/Task Force Timeline (after 2017 ESTRO meeting to December 2017)
FR: Falk Roeder; CF: Carlos Ferrer; MJ: Marta Jayes; PP: Philip Poortmans; FC: Felipe Calvo; FS: Felix Sedlmayer; ES: Elena Sperk; CL: Cristina Leonardi; CS: Claudio Sole; MK: Marco Krengli; HR: Harm Rutten
INVOLVED MEMBERS
ACTION STATUS
MJ ESTRO office provide ACROP latest guidelines and minutes from 07.05.2017 meeting Received FC May 2017
FC ACROP Guidelines + recommendations (FC) circulation among responsible authors Done 01.06.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF
Elaboration proposal guidelines (ACROP based) by site/type and sent to FC + PP
Expected 15.09.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Review (FC + PP) and re-circulation all authors/all guidelines for comments Expected 15.10.2017
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Working groups by cancer site/type submit a pre-definitive draft of guideline Agree already 15.11.207
FC, MK, HR,CS,FS, CL,ES,FR,CF,PP
Definitive manuscripts available from all groups Agree already 15.12.2017
PP FC MJ
Submission to ACROP Agree already 31.12.2017
Top Related